A randomized open study to compare the efficacy and safety of GLP-1 analogue (Liraglutide) versus DPP-4 inhibitor (Vildagliptin) in patients with Type 2 Diabetes.
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000004953
- Lead Sponsor
- Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 80
Not provided
1)Hypersensitivity to or contraindication of Liraglutide and Vildagliptin 2)None Type 2 diabetes 3)Medical history and/or complication of Diabetic ketoacidosis 4)Medical history and/or complication of severe hypoglycemia 5)Insulin treatment within 4 weeks prior to the study 6)Treatment with Liraglutide or Vildagliptin within 12 weeks prior to the study 7)New or Change treatment with Glucocorticoid 8)Unstable glycemic contol 9)Ccr(Cockcraft) < 30mL/h or sCre > 2.5 mg/dL(male), > 2.0mg/dL (Female) 10)AST or ALT >=2.5 time of institutional upper normal limit 11)Uncontrolled hypertension(systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg) 12)Severe health problems not suitable for the study 13)Pregnant or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method